Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis - SAHPRA

Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

Home > Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

17 Aug Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

Posted at 12:36h in by

2020 Nov

Download latest version
Document Number: DHCPL
Version: 1
Date Updated: 19/11/2020
File Type: pdf
Category: Communication To Health Care Professionals
Unit: Pharmacovigilance